Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials
Riccardo Proietti,1,2 Jacqueline Joza,1 Andrea Arensi,2 Michael Levi,1 Vincenzo Russo,3 Apostolos Tzikas,4 Paolo Danna,2 Antonio Sagone,2 Maurizio Viecca,2 Vidal Essebag1,5 1McGill University Health Center, Montreal, QC, Canada; 2Cardiology Department, Luigi Sacco Hospital, Milano, Italy; 3Cardiolo...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/7e2b8f66f5394499b453eeea086b4aca |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:7e2b8f66f5394499b453eeea086b4aca |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:7e2b8f66f5394499b453eeea086b4aca2021-12-02T06:49:29ZNovel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials1179-1470https://doaj.org/article/7e2b8f66f5394499b453eeea086b4aca2015-01-01T00:00:00Zhttp://www.dovepress.com/novel-nonpharmacologic-approaches-for-stroke-prevention-in-atrial-fibr-peer-reviewed-article-MDERhttps://doaj.org/toc/1179-1470 Riccardo Proietti,1,2 Jacqueline Joza,1 Andrea Arensi,2 Michael Levi,1 Vincenzo Russo,3 Apostolos Tzikas,4 Paolo Danna,2 Antonio Sagone,2 Maurizio Viecca,2 Vidal Essebag1,5 1McGill University Health Center, Montreal, QC, Canada; 2Cardiology Department, Luigi Sacco Hospital, Milano, Italy; 3Cardiology Department, Second University of Naples, Monaldi Hospital, Naples, Italy; 4Interbalkan European Medical Centre, Thessaloniki, Greece; 5Hôpital Sacré-Coeur de Montréal, Montreal, QC, Canada Abstract: Atrial fibrillation (AF), the most common cardiac arrhythmia, confers a 5-fold risk of stroke that increases to 17-fold when associated with mitral stenosis. At this time, the most effective long-term solution to protect patients from stroke and thromboembolism is oral anticoagulation, either with vitamin K antagonists (VKAs) or a novel oral anticoagulant (NOAC). Despite the significant benefits they confer, both VKAs and NOACs are underused because of their increased potential for bleeding, and VKAs are underused because of their narrow therapeutic range, need for regular international normalized ratio checks, and interactions with food or medications. In patients with nonvalvular AF, approximately 90% of strokes originate from the left atrial appendage (LAA); in patients with rheumatic mitral valve disease, many patients (60%) have strokes that originate from the left atrium itself. Surgical LAA amputation or closure, although widely used to reduce stroke risk in association with cardiac surgery, is not currently performed as a stand-alone operation for stroke risk reduction because of its invasiveness. Percutaneous LAA closure, as an alternative to anticoagulation, has been increasingly used during the last decade in an effort to reduce stroke risk in nonvalvular AF. Several devices have been introduced during this time, of which one has demonstrated noninferiority compared with warfarin in a randomized controlled trial. This review describes the available technologies for percutaneous LAA closure, as well as a summary of the published trials concerning their safety and efficacy in reducing stroke risk in AF. Keywords: left atrial appendage closure, atrial fibrillation, CHADSProietti RJoza JArensi ALevi MRusso VTzikas ADanna PSagone AViecca MEssebag VDove Medical PressarticleMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol 2015, Iss default, Pp 103-114 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medical technology R855-855.5 |
| spellingShingle |
Medical technology R855-855.5 Proietti R Joza J Arensi A Levi M Russo V Tzikas A Danna P Sagone A Viecca M Essebag V Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials |
| description |
Riccardo Proietti,1,2 Jacqueline Joza,1 Andrea Arensi,2 Michael Levi,1 Vincenzo Russo,3 Apostolos Tzikas,4 Paolo Danna,2 Antonio Sagone,2 Maurizio Viecca,2 Vidal Essebag1,5 1McGill University Health Center, Montreal, QC, Canada; 2Cardiology Department, Luigi Sacco Hospital, Milano, Italy; 3Cardiology Department, Second University of Naples, Monaldi Hospital, Naples, Italy; 4Interbalkan European Medical Centre, Thessaloniki, Greece; 5Hôpital Sacré-Coeur de Montréal, Montreal, QC, Canada Abstract: Atrial fibrillation (AF), the most common cardiac arrhythmia, confers a 5-fold risk of stroke that increases to 17-fold when associated with mitral stenosis. At this time, the most effective long-term solution to protect patients from stroke and thromboembolism is oral anticoagulation, either with vitamin K antagonists (VKAs) or a novel oral anticoagulant (NOAC). Despite the significant benefits they confer, both VKAs and NOACs are underused because of their increased potential for bleeding, and VKAs are underused because of their narrow therapeutic range, need for regular international normalized ratio checks, and interactions with food or medications. In patients with nonvalvular AF, approximately 90% of strokes originate from the left atrial appendage (LAA); in patients with rheumatic mitral valve disease, many patients (60%) have strokes that originate from the left atrium itself. Surgical LAA amputation or closure, although widely used to reduce stroke risk in association with cardiac surgery, is not currently performed as a stand-alone operation for stroke risk reduction because of its invasiveness. Percutaneous LAA closure, as an alternative to anticoagulation, has been increasingly used during the last decade in an effort to reduce stroke risk in nonvalvular AF. Several devices have been introduced during this time, of which one has demonstrated noninferiority compared with warfarin in a randomized controlled trial. This review describes the available technologies for percutaneous LAA closure, as well as a summary of the published trials concerning their safety and efficacy in reducing stroke risk in AF. Keywords: left atrial appendage closure, atrial fibrillation, CHADS |
| format |
article |
| author |
Proietti R Joza J Arensi A Levi M Russo V Tzikas A Danna P Sagone A Viecca M Essebag V |
| author_facet |
Proietti R Joza J Arensi A Levi M Russo V Tzikas A Danna P Sagone A Viecca M Essebag V |
| author_sort |
Proietti R |
| title |
Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials |
| title_short |
Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials |
| title_full |
Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials |
| title_fullStr |
Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials |
| title_full_unstemmed |
Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials |
| title_sort |
novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://doaj.org/article/7e2b8f66f5394499b453eeea086b4aca |
| work_keys_str_mv |
AT proiettir novelnonpharmacologicapproachesforstrokepreventioninatrialfibrillationresultsfromclinicaltrials AT jozaj novelnonpharmacologicapproachesforstrokepreventioninatrialfibrillationresultsfromclinicaltrials AT arensia novelnonpharmacologicapproachesforstrokepreventioninatrialfibrillationresultsfromclinicaltrials AT levim novelnonpharmacologicapproachesforstrokepreventioninatrialfibrillationresultsfromclinicaltrials AT russov novelnonpharmacologicapproachesforstrokepreventioninatrialfibrillationresultsfromclinicaltrials AT tzikasa novelnonpharmacologicapproachesforstrokepreventioninatrialfibrillationresultsfromclinicaltrials AT dannap novelnonpharmacologicapproachesforstrokepreventioninatrialfibrillationresultsfromclinicaltrials AT sagonea novelnonpharmacologicapproachesforstrokepreventioninatrialfibrillationresultsfromclinicaltrials AT vieccam novelnonpharmacologicapproachesforstrokepreventioninatrialfibrillationresultsfromclinicaltrials AT essebagv novelnonpharmacologicapproachesforstrokepreventioninatrialfibrillationresultsfromclinicaltrials |
| _version_ |
1718399699549945856 |